KBC Group
RVMD icon

KBC Group’s Revolution Medicines RVMD Stock Holding History

KBC Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.3M Buy
54,814
+26,678
+95% +$5.29M 0.02% 374
2026
Q2 		$5.27M Buy
28,136
+12,741
+83% +$1.86M 0.01% 494
2026
Q1 		$1.5M Buy
15,395
+11,196
+267% +$1.13M ﹤0.01% 696
2025
Q4 		$334K Hold
4,199
– – ﹤0.01% 774
2025
Q3 		$196K Hold
4,199
– – ﹤0.01% 913
2025
Q2 		$154K Sell
4,199
-1,932
-32% -$74.2K ﹤0.01% 975
2025
Q1 		$217K Buy
6,131
+1,152
+23% +$46.8K ﹤0.01% 1025
2024
Q4 		$218K Buy
4,979
+1,758
+55% +$88.7K ﹤0.01% 1081
2024
Q3 		$146K Buy
3,221
+368
+13% +$16K ﹤0.01% 1067
2024
Q2 		$111K Buy
2,853
+592
+26% +$22.1K ﹤0.01% 1110
2024
Q1 		$73K Hold
2,261
– – ﹤0.01% 1308
2023
Q4 		$65K Buy
2,261
+1,034
+84% +$24.8K ﹤0.01% 1346
2023
Q3 		$34K Buy
+1,227
New +$36.4K ﹤0.01% 1731

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

KBC Group's RVMD Position: Q3 2026 in Review

KBC Group increased its Revolution Medicines (RVMD) stake by 95% in Q3 2026, buying an estimated $5.29M and bringing the position to 54,814 shares worth $11.3M. The position accounts for 0.02% of the portfolio, ranked #374.

KBC Group first reported a position in RVMD in Q3 2023 and has held it in 13 quarters since. 577 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • KBC Group held 54,814 shares of Revolution Medicines worth $11.3M as of Q3 2026.
  • KBC Group bought 26,678 Revolution Medicines shares in Q3 2026, an estimated $5.29M.
  • Revolution Medicines made up 0.02% of KBC Group's portfolio in Q3 2026, its #374 holding.
  • KBC Group first reported a position in Revolution Medicines in Q3 2023 and has held it in 13 quarters since.
  • 577 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.